Patents by Inventor Axel Metzger

Axel Metzger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sting agonists for treating bladder cancer and solid tumors
    Patent number: 11883420
    Abstract: Methods for treating bladder cancer and solid tumors are disclosed. The methods include administering to a patient a compound of formula 1 Pharmaceutical compositions of compound 1 are also disclosed.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: January 30, 2024
    Assignee: VENENUM BIODESIGN, LLC
    Inventors: Brian F. McGuinness, Grant Gallagher, Michael S. McQueney, Rukiye Nazan Eraslan, Gary Schieven, Jason Trama, Axel Metzger, David J. Diller, David E. Kaelin
  • Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications
    Publication number: 20230040236
    Abstract: Melanocortin receptor-specific cyclic peptide or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions or formulations and methods of preventing, ameliorating or treating melanocortin receptor-medicated diseases, indications, conditions and syndromes, including ocular indications, utilizing the cyclic peptide of the foregoing formula.
    Type: Application
    Filed: July 11, 2022
    Publication date: February 9, 2023
    Applicant: PALATIN TECHNOLOGIES, INC.
    Inventors: Wei YANG, John H. DODD, Axel METZGER
  • Orally Active Melanocortin Receptor-4 Compounds
    Publication number: 20220204450
    Abstract: A compound of the formula where R1, R2, R3, R4, R5, R6a, and R6b are as defined in the specification and claims, or an enantiomer, stereoisomer or diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, and the use thereof in the treatment of diseases, disorders, syndromes and conditions responsive to modulation of a melanocortin receptor.
    Type: Application
    Filed: March 9, 2022
    Publication date: June 30, 2022
    Applicant: Palatin Technologies, Inc.
    Inventors: James Bullington, Axel Metzger, John H. Dodd
  • NOVEL STING AGONISTS
    Publication number: 20220048936
    Abstract: The present invention provides compounds of Formula I?: wherein W, X, Y, Z, Z1, Z2, R1, R2, R3, R4 and R5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.
    Type: Application
    Filed: September 7, 2021
    Publication date: February 17, 2022
    Applicant: Venenum Biodesign, LLC
    Inventors: David J. DILLER, Axel METZGER, David E. KAELIN, JR., Steven PAGET, Chia-Yu HUANG, Brian F. MCGUINNESS, Audrey Julie HOSPITAL, William Ronald SOLVIBILE, JR.
  • Sting agonists
    Patent number: 11161864
    Abstract: The present invention provides compounds of Formula I?: wherein , W, X, Y, Z, Z1, Z2, R1, R2, R3, R4 and R5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: November 2, 2021
    Assignee: VENENUM BIODESIGN, LLC
    Inventors: David J. Diller, Axel Metzger, David E. Kaelin, Jr., Steven Paget, Chia-Yu Huang, Brian F. Mcguinness, Audrey Julie Hospital, William Ronald Solvibile, Jr.
  • STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS
    Publication number: 20210290645
    Abstract: Methods for treating bladder cancer and solid tumors are disclosed. The methods include administering to a patient a compound of formula 1 Pharmaceutical compositions of compound 1 are also disclosed.
    Type: Application
    Filed: June 8, 2021
    Publication date: September 23, 2021
    Applicant: Venenum Biodesign, LLC
    Inventors: Brian F. McGUINNESS, Grant GALLAGHER, Michael S. McQUENEY, Rukiye NAZAN ERASLAN, Gary SCHIEVEN, Jason TRAMA, Axel METZGER, David J. DILLER, David E. KAELIN
  • Sting agonists for treating bladder cancer and solid tumors
    Patent number: 11110106
    Abstract: Methods for treating bladder cancer and solid tumors are disclosed. The methods include administering to a patient a compound of formula 1 Pharmaceutical compositions of compound 1 are also disclosed.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: September 7, 2021
    Assignee: VENENUM BIODESIGN, LLC
    Inventors: Brian F. McGuinness, Grant Gallagher, Michael S. McQueney, Rukiye Nazan Eraslan, Gary Schieven, Jason Trama, Venugopalareddy Bommireddy Venkata, Axel Metzger, David J. Diller, David E. Kaelin
  • Orally Active Melanocortin Receptor-4 Compounds
    Publication number: 20210198201
    Abstract: A compound of the formula where R1, R2, R3, R4, R5, R6a, and R6b are as defined in the specification and claims, or an enantiomer, stereoisomer or diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, and the use thereof in the treatment of diseases, disorders, syndromes and conditions responsive to modulation of a melanocortin receptor.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 1, 2021
    Inventors: James Bullington, Axel Metzger, John Harold Dodd
  • NOVEL STING AGONISTS
    Publication number: 20200131209
    Abstract: The present invention provides compounds of Formula I?: wherein , W, X, Y, Z, Z1, Z2, R1, R2, R3, R4 and R5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.
    Type: Application
    Filed: October 24, 2019
    Publication date: April 30, 2020
    Inventors: David J. Diller, Axel Metzger, David E. Kaelin, JR., Steven Paget, Chia-Yu Huang, Brian F. Mcguinness, Audrey Julie Hospital, William Ronald Solvibile, JR.
  • Melanocortin receptor-specific spiro-piperidine compounds
    Patent number: 8263608
    Abstract: Melanocortin receptor-specific compounds of formula I below: wherein the variables are as defined in the specification, and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: September 11, 2012
    Assignee: Palatin Technologies, Inc.
    Inventors: Yi-Qun Shi, John H. Dodd, Elizabeth G. Rowley, Gary L. Olson, Axel Metzger
  • N-heterocyclic inhibitors of TNF-alpha expression
    Patent number: 8044040
    Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I): Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: October 25, 2011
    Assignees: Bristol-Myers Squibb Company, Pharmacopeia, Inc.
    Inventors: Gulzar Ahmed, Axel Metzger, Ian Henderson, David J. Diller, Jun Wen, Stephen T. Wrobleski, Katerina Leftheris, Chunjian Liu
  • 8-HETEROARYLPURINE MNK2 INHIBITORS FOR TREATING METABOLIC DISORDERS
    Publication number: 20110230480
    Abstract: Compounds of the formula are disclosed as Mnk2 inhibitors which are useful for the treatment and prevention of metabolic disorders such as obesity and diabetes.
    Type: Application
    Filed: May 27, 2011
    Publication date: September 22, 2011
    Inventors: Andrew G. Cole, Marc-Raleigh Brescia, Joan J. Zhang, Zahid Hussain, David J. Diller, Axel Metzger, Gulzar Ahmed, Ian Henderson
  • Melanocortin Receptor-Specific Spiro-Piperidine Compounds
    Publication number: 20110178080
    Abstract: Melanocortin receptor-specific compounds of formula I below: wherein the variables are as defined in the specification, and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders.
    Type: Application
    Filed: March 29, 2011
    Publication date: July 21, 2011
    Applicant: PALATIN TECHNOLOGIES, INC.
    Inventors: Yi-Qun Shi, John H. Dodd, Elizabeth G. Rowley, Gary L. Olson, Axel Metzger
  • 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders
    Patent number: 7951803
    Abstract: Compounds of the formula wherein R1 represents optionally substituted C1-C10 alkyl, aryl or heteroaryl, and R3 represents alkoxy-substituted aryl or optionally substituted heteroaryl, are disclosed as Mnk2 inhibitors which are useful for the treatment and prevention of metabolic disorders such as obesity and diabetes.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: May 31, 2011
    Assignee: Pharmacopeia, LLC
    Inventors: Andrew G. Cole, Marc-Raleigh Brescia, Joan J. Zhang, Zahid Hussain, David J. Diller, Axel Metzger, Gulzar Ahmed, Ian Henderson
  • Purinone derivatives for treating neurodegenerative diseases
    Publication number: 20090023723
    Abstract: The invention relates to purinone derivatives useful in treating disorders that are mediated by adenosine receptor function, including neurodegenerative diseases and inflammation.
    Type: Application
    Filed: September 21, 2006
    Publication date: January 22, 2009
    Applicant: Pharmacopeia Drug Discovery, Inc.
    Inventors: Andrew G. Cole, Ian Henderson, Marc-Raleigh Brescia, Axel Metzger, Lan-Ying Qin, Gulzar Ahmed, Brian F. McGuinness, Yuefei Shao, Jingqi Duo
  • N-heterocyclic inhibitors of TNF-? expression
    Patent number: 7479495
    Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: January 20, 2009
    Assignees: Pharmacopeia, Inc., Bristol-Myers Squibb Company
    Inventors: Kevin Joseph Moriarty, Yvonne Shimshock, Gulzar Ahmed, Junjun Wu, James Wen, Wei Li, Shawn David Erickson, Jeffrey John Letourneau, Edward McDonald, Katerina Leftheris, Stephen T. Wrobleski, Zahid Hussain, Ian Henderson, Axel Metzger, John J. Baldwin, Alaric J. Dyckman
  • Substituted 2-aminothiazoles for treating neurodegenerative diseases
    Publication number: 20090005568
    Abstract: The invention relates to substituted 2-aminothiazole derivatives useful in treating disorders that are mediated by A2a receptor function, including neurodegenerative diseases including Parkinson's disease and inflammation.
    Type: Application
    Filed: August 18, 2006
    Publication date: January 1, 2009
    Applicant: Pharmacopeia Drug Discovery, Inc.
    Inventors: Andrew G. Cole, Axel Metzger, Ian Henderson
  • 8-HETEROARYLPURINE MNK2 INHIBITORS FOR TREATING METABOLIC DISORDERS
    Publication number: 20080032971
    Abstract: Compounds of the formula are disclosed as Mnk2 inhibitors which are useful for the treatment and prevention of metabolic disorders such as obesity and diabetes.
    Type: Application
    Filed: March 9, 2007
    Publication date: February 7, 2008
    Applicant: PHARMACOPEIA DRUG DISCOVERY, INC.
    Inventors: Andrew Cole, Marc-Raleigh Brescia, Joan Zhang, Zahid Hussain, David Diller, Axel Metzger, Gulzar Ahmed, Ian Henderson
  • N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION
    Publication number: 20080015185
    Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I): Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.
    Type: Application
    Filed: July 16, 2007
    Publication date: January 17, 2008
    Inventors: Gulzar Ahmed, Axel Metzger, Ian Henderson, David J. Diller, Jun Wen, Stephen T. Wrobleski, Katerina Leftheris, Chunjian Liu
  • N-heterocyclic inhibitors of TNF-? expression
    Patent number: 7253174
    Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I): Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: August 7, 2007
    Assignees: Bristol-Myers Squibb Company, Pharmacopeia, Inc.
    Inventors: Gulzar Ahmed, Axel Metzger, Ian Henderson, David J. Diller, Jun Wen, Stephen T. Wrobleski, Katerina Leftheris, Chunjian Liu